PRF Technologies Ltd. PRFX 深 滬
等待開盤 04-17 09:30:00 美东时间
2.68
-0.010
-0.37%
華盛通- 最 高2.75
- 今 開2.66
- 成交量 1.92万股
- 最 低 2.65
- 昨 收 2.69
- 總市值 226.34万
- 52周最高 17.95
- 市盈率 靜 --
- 換手率 2.28%
- 52周最低 1.7968
- 委 比 -11.93%
- 總股本 84.46万
- 歷史最高 9420.00
- 量 比 0.30
- 振 幅 3.72%
- 歷史最低 2.65
- 每 手 1
- 風險率 2.62%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What's Going On With Pharma Company PRF Technologies On Tuesday?
PRF Technologies outlines 2025 progress, with OcuRing-K ocular drug-delivery advancement and AI solar analytics growth.
04-07 23:02
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Profusa (NASDAQ:PFSA) shares rose 148.0% to $1.88 during Monday's regul...
04-07 01:05
PRF Technologies In FY25 Had ~$4.1M In Cash, Cash Equivalents, Short-Term Deposits And Restricted Cash And Positive Working Capital Of ~$1.9M
LayerBio's OcuRing™-K program and broader ocular platform strengthen PRF's healthcare growth strategyDeepSolar advances from acquisition to early commercial deployment
03-27 20:05
PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms
PRF Technologies Ltd. reported strategic advancements in healthcare and renewable energy in 2025, with the acquisition of LayerBio and DeepSolar marking its expansion into AI-driven solar analytics and sustained-release ocular therapies. The LayerBio acquisition advanced OcuRing™-K, a drop-less intraocular ring for post-cataract pain management, with preclinical and Phase I data supporting its safety and efficacy. PRF also expanded DeepSolar's co...
03-27 12:00
PRF Technologies Partnters With Blade Ranger Over Commercial Expansion Of Its DeepSolar Platform
PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") today announced a commercial collaboration agreement with Blade Ranger Ltd. (TASE: BLRN) designed to accelerate the commercial expansion of its DeepSolar
03-17 20:35
PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements
PRF Technologies has teamed up with Blade Ranger to expand DeepSolar's reach in utility-scale solar markets. The partnership aims to secure multiple large-scale deployments, each targeting at least 150 MW. DeepSolar's AI platform enhances solar asset performance through improved forecasting, diagnostics, and real-time monitoring. This collaboration harnesses Blade Ranger's global renewable energy network to drive commercial growth amid a rapidly ...
03-17 12:30
PRF Technologies Strikes Agreement With Shikun & Binui Energy To Deploy DeepSolar At 71-MW Satu Mare Photovoltaic Site In Romania
PRF Technologies (Nasdaq: PRFX) ("PRF" or the "Company"), through its DeepSolar™ AI-driven solar analytics business unit, today announced the signing of a software-as-a-service (SaaS) agreement with Shikun &
02-11 21:35
PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar’s Installed Commercial Base
Shikun & Binui Energy has selected DeepSolar's AI-driven solar analytics platform for its 71 MW Satu Mare solar project in Romania, marking a significant step in DeepSolar's expansion in European renewable-energy markets. The partnership aims to enhance operational efficiency and support data-driven decision-making through advanced analytics and performance monitoring. This deployment reflects Shikun & Binui Energy's growing presence in European ...
02-11 13:30
Why PainReform Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket
Shares of PainReform Ltd. (NASDAQ:PRFX) rose sharply in pre-market trading. The...
01-16 17:38
PainReform’s LayerBio’s Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies
PainReform Ltd. and LayerBio, Inc. announced safety data supporting the continued development of OcuRing™-K, a drop-less, sustained-release ocular drug delivery platform for use in cataract surgery. Preclinical rabbit studies and a Phase I clinical study demonstrated a favorable safety profile, with no treatment-related safety concerns observed. The platform's sustained-release mechanism aims to minimize local irritation and systemic exposure. Pa...
01-12 14:00
